Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab extension study in juvenile psoriatic arthritis and enthesitis-related arthritis
NCT03769168Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of secukinumab in juvenile psoriatic arthritis (JPsA), enthesitis-related juvenile idiopathic arthritis (ERA), sponsored by Novartis. Started Jun 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
juvenile psoriatic arthritis (JPsA)enthesitis-related juvenile idiopathic arthritis (ERA)
Beyond the preview
Go deeper on NCT03769168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769168.